Showing 1 - 4 results of 4 for search 'Alba López Bravo', query time: 0.03s Refine Results
  1. 1
    Cutaneous Allodynia in Migraine: A Narrative Review

    Cutaneous Allodynia in Migraine: A Narrative Review by Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Sonia Quintas, Noemí Morollón Sánchez-Mateos, Alba López-Bravo, Alba López-Bravo, Marta Vila-Pueyo, Vesselina Grozeva, Robert Belvís, Sonia Santos-Lasaosa, Sonia Santos-Lasaosa, Pablo Irimia

    Published 2022-01-01
    Get full text
    Article
  2. 2
    Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies

    Dysautonomia in COVID-19 Patients: A Narrative Review on Clinical Course, Diagnostic and Therapeutic Strategies by Francisco Carmona-Torre, Francisco Carmona-Torre, Francisco Carmona-Torre, Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Ane Mínguez-Olaondo, Alba López-Bravo, Alba López-Bravo, Beatriz Tijero, Beatriz Tijero, Beatriz Tijero, Vesselina Grozeva, Michaela Walcker, Harkaitz Azkune-Galparsoro, Harkaitz Azkune-Galparsoro, Harkaitz Azkune-Galparsoro, Adolfo López de Munain, Adolfo López de Munain, Adolfo López de Munain, Adolfo López de Munain, Adolfo López de Munain, Adolfo López de Munain, Ana Belen Alcaide, Ana Belen Alcaide, Jorge Quiroga, Jorge Quiroga, Jorge Quiroga, Jorge Quiroga, Jose Luis del Pozo, Jose Luis del Pozo, Jose Luis del Pozo, Juan Carlos Gómez-Esteban, Juan Carlos Gómez-Esteban, Juan Carlos Gómez-Esteban, Juan Carlos Gómez-Esteban, Juan Carlos Gómez-Esteban, Juan Carlos Gómez-Esteban

    Published 2022-05-01
    Get full text
    Article
  3. 3
    Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

    Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from th... by Victor Obach, Fernando Velasco, Rocio Alvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Neus Fabregat, Teresa Marco, Aintzine Ruisanchez, Natalia Roncero, Ane Mínguez-Olaondo, Marta Ruibal, Daniel Guisado-Alonso, Antia Moreira, Elisa Cuadrado-Godia, Amaya Echeverria, Izaro Kortazar Zubizarreta, Alba López-Bravo, Nuria Riesco, Lucia González-Fernández, Nuria Pola, Paula Manera, Ángel Luis Guerrero-Peral, Agustín Oterino Duran, Yésica González-Osorio, Rosario Armand, Santiago Fernández-Fernández, David García-Azorín, Juan Carlos García-Moncó

    Published 2023-11-01
    Get full text
    Article
  4. 4
    Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

    Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients by Albert Muñoz-Vendrell, Sergio Campoy, Edoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, Candela Nieves Castellanos, Marina Olivier, Jaume Campdelacreu, Joan Prat, Javier Camiña Muñiz, Francisco José Molina Martínez, Ane Mínguez-Olaondo, Marta Ruibal Salgado, Sonia Santos Lasaosa, María Pilar Navarro Pérez, Noemí Morollón, Alba López Bravo, Luis Miguel Cano Sánchez, Sonia María García-Sánchez, Jésica García-Ull, Laura Rubio-Flores, Alicia Gonzalez-Martinez, Sonia Quintas, Ana Echavarría Íñiguez, Sendoa Gil Luque, María Victoria Castro-Sánchez, Vanesa Adell Ortega, Jessica García Alhama, Nuria Berrocal-Izquierdo, Robert Belvís, Samuel Díaz-Insa, Patricia Pozo-Rosich, Mariano Huerta-Villanueva

    Published 2023-06-01
    Get full text
    Article

Search Tools: